Pfizer’s COVID-19 Vaccine for Children Appears Nearly 91% Safe and Effective to prevent symptomatic infection in children aged 5 to 11 years, According to details of a study by the company released this Friday, at a time when the United States government determines whether to include that age group in the vaccination campaign.
Vaccination could begin in early November and the first children in line they would be fully protected for Christmas if the regulators give you the green light.
Details of the Pfizer study were posted online. The Food and Drug Administration (FDA) is expected to release its independent evaluation of the safety and effectiveness of the vaccine in the next few hours.
FDA advisers will publicly debate the tests next week. If they authorize the vaccines, the Centers for Disease Control and Prevention (CDC) will have the final say on who should receive them.
Pfizer maximum strength vaccines are already licensed for people 12 years of age and older, but pediatricians and many parents eagerly await immunization of children under that age to prevent contagion of the aggressive delta variant and allow the children to go to school.
More than 25,000 pediatricians and primary care providers have already signed up to introduce injections into small arms.
The administration of President Joe Biden has purchased enough pediatric doses – in special orange-capped vials to distinguish them from the adult vaccine – for the approximately 28 million children ages five to 11 in the United States. If the vaccine is approved, 11 million doses will be shipped nationwide immediately, together with needles of the corresponding size.
A Pfizer study included 2,268 boys of those ages who received two doses three weeks apart, whether it was a placebo or the vaccine. Each dose was a third of the amount inoculated in adolescents and adults.
The researchers calculated that the low-dose vaccine was almost 91% effective based on 16 cases of COVID-19 in children inoculated with the placebo compared to three cases in those vaccinated. None of the children suffered a serious illness, but the vaccinated exhibited much milder symptoms than the unvaccinated.
In addition, the levels of antibodies developed in the children who received the low doses were as high as in the adolescents and adults who received the regular vaccine.